Why Gilead Sciences, inc. Stock Was Flat Today
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 24, 6:07PM CDT
Gilead Sciences turned in an incredible quarter yesterday, with revenue of $6.5 billion beating analyst expectations by 12% and more than doubling the year-ago quarter. The difference in earnings was even starker: Adjusted EPS of $2.36...
Final Glance: Biotechnology companies
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Celgene, Alexion Beat Estimates, But Biotechs Fall
at Investor's Business Daily - Thu Jul 24, 4:07PM CDT
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene's (CELG) Q2 earnings rose 18% over the...
3 Crucial Quotes From Gilead Sciences Stock
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 24, 4:05PM CDT
Gilead Sciences is a long-standing leader in HIV treatment, but its sales of its hepatitis C drug Sovaldi that's driving the company's revenue surge. While Sovaldi's sales are soaring, investors are right to wonder if the drug's break neck...
Avella Chosen as Specialty Pharmacy Partner for Zydelig(R)
Newsfile Corp - Thu Jul 24, 3:29PM CDT
full story)
What Gilead Stock's Latest Blockbuster Approval Means for Investors
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 24, 3:01PM CDT
Source: Gilead Sciences Gilead Sciences has won approval for its promising drug Zydelig in three important cancer indications. As a combination treatment alongside Roche's top selling Rituxan, the FDA green-light puts Zydelig head-to-head...
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:45PM CDT
Alexion (ALXN) reported in line earnings in the second quarter.
3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmit
George Budwell, The Motley Fool - Motley Fool - Thu Jul 24, 1:05PM CDT
The health care sector exploded with major news events yesterday, fueled by second-quarter earnings, clinical trial updates, and even unexpected regulatory events. Given that the day's headlines seemed to be dominated by Puma Biotechnology 's...
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.
Most active Nasdaq-traded stocks
AP - Thu Jul 24, 12:23PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Midday Glance: Biotechnology companies
AP - Thu Jul 24, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
3 Stocks Improving Performance Of The Health Care Sector
at The Street - Thu Jul 24, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Video: Celgene, Alexion Earnings Top, But Stocks Fall
at Investor's Business Daily - Thu Jul 24, 10:39AM CDT
Big-cap biotechs Celgene (CELG) and Alexion Pharmaceuticals (ALXN) both modestly beat Q2 estimates and raised their guidance Thursday morning, but their shares were falling in the stock market today as Wall Street seemed to hope for more. Celgene's...
Early Glance: Biotechnology companies
AP - Thu Jul 24, 10:37AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Jim Cramer's Mad Dash: Gilead Sciences Still Has Upside
at The Street - Thu Jul 24, 10:11AM CDT
TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, argued that shares of Gilead Sciences are not expensive given its growth rate.
Stock Market News for July 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 9:10AM CDT
Benchmarks finished mostly higher on Wednesday following upbeat quarterly results from healthcare and technology companies
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
ACCESSWIRE - Thu Jul 24, 9:03AM CDT
WHITEFISH, MT / July 24, 2014 / Fat is driving the bus these days in one narrow, but widening, biotech sector as companies strive for dominance. Among these are Galectin Therapeutics Inc. (NASDAQ: GALT), Intercept Pharmaceuticals (NASDAQ: ICPT), Raptor Pharmaceuticals (NASDAQ: RPTP) and Gilead Sciences (NASDAQ: GILD), all of which are in search of a cure for one stage or another of "fatty liver disease."
Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:50AM CDT
Gilead (GILD) blew away estimates on strong Sovaldi sales.
Today's Momo Momentum Stock To Watch: Gilead (GILD)
at The Street - Thu Jul 24, 8:45AM CDT
Trade-Ideas LLC identified Gilead (GILD) as a momo momentum candidate
Gilead Sciences partners with the Medicines Patent Pool to expand access of TAF for HIV treatment in the developing world
M2 - Thu Jul 24, 6:52AM CDT
Biopharmaceutical company Gilead Sciences (NasdaqGS:GILD) on Thursday launched a new agreement to expand access to its investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine's US regulatory approval in partnership with the Medicines Patent Pool (MPP).